Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CRANBURY, N.J., Feb. 06, 2017 -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Leerink Partners 6th Annual Global Healthcare Conference in New York, NY on Thursday, February 16, 2017 at 11 a.m. ET.
A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044 Media: MWW PR Sid Dinsay [email protected] (646) 381-9017
